Osaka, Japan - December 10, 2020 - Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the launch of two generic drugs with 10 strengths. They will be launched sequentially beginning December 11, 2020. Sawai’s product line now includes 322 compounds with 786 strengths.
The list of new products
1. Pregabalin OD Tablets, Capsules
| Generic name | Pregabalin |
|---|---|
| Strengths | OD Tablets, Capsules: 25 mg, 75 mg, 150 mg |
| Brand products | Lyrica® OD Tablets 25 mg, 75 mg, 150 mg, Lyrica® Capsules 25 mg, 75 mg, 150 mg |
2. Rivastigmine Tapes
| Generic name | Rivastigmine |
|---|---|
| Strengths | 4.5 mg, 9 mg, 13.5 mg, 18 mg |
| Brand products | EXELON® PATCH 4.5 mg, 9 mg, 13.5 mg, 18 mg, RIVASTACH® Patches 4.5 mg, 9 mg, 13.5 mg, 18 mg |
Striking Features (Partial list)
Pregabalin OD Tablets, Capsules
Sawai is launching the first generic of this product, which is used to treat neuropathic pain and pain associated with fibromyalgia. We offer two dosage forms, OD tablets and capsules. “Generic name” and “Strength” are printed on both sides of the OD tablets. OD tablets are menthol-scented.
The capsules are printed with the “Generic name” and “Strength”.
The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.